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It is well established that ultraviolet radiation has
immunomodulatory effects that may be involved in
skin cancer. Recent studies have shown that ultra-
violet A radiation (320±400 nm) as well as ultraviolet
B (290±320 nm) is immunosuppressive. This means
sunscreens that mainly absorb ultraviolet B (pro-
tection against erythema) may be less effective in
preventing ultraviolet radiation-induced immuno-
suppression than broad-spectrum products. We have
studied the effects of ultraviolet A exposure on the
human delayed-type hypersensitivity response and
compared the ef®cacy of sunscreens having different
levels of ultraviolet A protection under both solar-
simulated radiation and outdoor real-life solar expo-
sure conditions. Delayed-type hypersensitivity was
assessed using recall antigens. In a ®rst study, two
groups of volunteers were exposed to ultraviolet A
(either full spectrum ultraviolet A or ultraviolet A1)
without prior application of sunscreen and they were
shown to exhibit signi®cantly reduced delayed-type
hypersensitivity responses. In order to compare the
ef®cacy of sunscreens in preventing photoimmuno-
suppression, three groups of subjects received 10
cumulative exposures to solar-simulated radiation;
one group was exposed unprotected and the other
two were exposed after being applied either a ultra-
violet B or a broad-spectrum sunscreen, each with
the same sun protection factor 9, but with different
ultraviolet A protection factors 9 and 2. Then, an
outdoor study was conducted in which delayed-type
hypersensitivity was assessed before and after six
daily exposures. Two different groups of subjects
were treated with one of two sunscreens having the
same sun protection factor 25 but different ultra-
violet A-protection factors. In unprotected volun-
teers, responses to delayed-type hypersensitivity tests
were signi®cantly reduced irrespective of ultraviolet
exposure conditions (full spectrum ultraviolet A,
ultraviolet A1, solar-simulated radiation). The ultra-
violet B sunscreen failed to protect from solar-
simulated radiation-induced immunosuppression. In
contrast, the broad-spectrum sunscreen having the
same sun protection factor but providing high
protection in the ultraviolet A range signi®cantly
reduced local ultraviolet-induced immunosuppres-
sion and prevented the distal effects. In the outdoor
study, as compared with delayed-type hypersensi-
tivity responses obtained before sun exposure, no
alteration of immune response was detected when
the skin was protected by broad-spectrum sunscreen
sun protection factor 25 and ultraviolet A-protection
factor 14. Conversely, a broad-spectrum sunscreen
sun protection factor 25 ultraviolet A-protection
factor 6 failed to protect against the sun-impaired
response. The above studies clearly demonstrate the
role of ultraviolet A in the induction of photo-
immunosuppression together with the need for sun-
screen products providing ef®cient photoprotection
throughout the entire ultraviolet spectrum. Key
words: human/photoimmunosuppression/sunscreens/ultra-
violet A. J Invest Dermatol 117:1186±1192, 2001
U
ltraviolet (UV) radiation has been shown to induce
immunosuppression in humans (Hersey et al, 1983;
Cooper et al, 1985; Kelly et al, 2000). Many studies
have reported the effects of UVB (290±320 nm)
radiation on immune responses such as contact
hypersensitivity (CHS) or delayed-type hypersensitivity (DTH)
reactions to haptens, but relatively few studies have addressed the
effects of UVA in humans (Hersey et al, 1983, 1987; LeVee et al,
1997; Skov et al, 1997; Damian et al, 1999). Some authors have
found that UVA had signi®cant suppressive effects on CHS
responses (Hersey et al, 1983; LeVee et al, 1997), whereas others
did not (Skov et al, 1997). Hersey et al (1987) reported that
UVA induced suppression of DTH response to recall antigens
(Multitest Pasteur/MeÂrieux). Damian et al (1999) showed that CHS
to nickel was suppressed after one to three exposures to low UVA
doses. Whereas commercially available sunscreens protected the
skin from in¯ammatory responses (erythema and edema), some
studies have shown that they provided little or no protection
against UV-induced immune suppression (Ho et al, 1992; van Praag
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et al, 1991). Others reported data showing that sunscreens could
completely prevent these effects (Wolf et al, 1993; Roberts and
Beasley, 1997).
It is not established whether the sun protection factor (SPF) of a
sunscreen can predict its ability to protect against photo-induced
immune suppression (Young and Walker, 1999). It is possible that
the degree of protection provided by a sunscreen not only depends
on the SPF but also on the absorption spectrum and in particular,
the absorbing potency it affords in the UVA range. Some studies
seem to indicate this trend (Bestak et al, 1995; Damian et al, 1997;
Serre et al, 1997; Fourtanier et al, 2000).
Here, we report studies in human volunteers to assess the role of
UVA in eliciting immune suppressive effects. We also investigated
whether broad-spectrum sunscreens were more effective than
sunscreens absorbing UVB only. We assessed the effects of either
UVA or solar-simulated radiation (SSR) or real sunlight on the
elicitation phase of the DTH response to recall antigens (Multitest
Pasteur/MeÂrieux).
MATERIALS AND METHODS
Subjects Female and male Caucasian volunteers were recruited after
study approval by an ethics committee. Study inclusion criteria included
Fitzpatrick skin type II or III (Fitzpatrick, 1988), aged between 18 and
40 y with general good health. Exclusion criteria included disease
conditions or medications causing immune suppression or the risk of
photosensitization. None of the volunteers had experienced sun exposure
for at least 4 wk prior to the study. Seventy-®ve subjects were recruited
for the indoor studies. Three of them dropped out for personal reasons
without any relation to the treatment. For the outdoor study, 32 subjects
were included and all completed the test. In each experiment the
volunteers were divided into groups of 11±16 volunteers with no sex
randomization, excepted for the outdoor study in which each group
included eight males and eight females (Table I).
In a ®rst experiment (study I), the effects of full spectrum UVA
(group 2) and UVA1 (group 3) were compared. Volunteers unexposed
to UVA (group 1) served as controls to measure the reaction variability
to Multitest antigens in the absence of UVA exposure.
In a second experiment (study II), we compared the ability of two
SPF 9 sunscreens to prevent immunosuppression induced by SSR
exposure (groups 5 and 6). A control group was exposed to SSR without
applying sunscreen prior to exposure (group 4). In a third experiment
(study III), two groups of 16 volunteers applied SPF 25 sunscreens before
being exposed to outdoor real sun exposure (groups 7 and 8).
In each study, the volunteers were assembled after an initial Multitest
on the back. They were then randomized into the different groups
according to their initial reaction to the Multitest in order to obtain a
similar average response between the groups excepted for study I group
3 which was added after the initial randomization.
UV sources and dosimetry
UVAÐStudy I Two UVA spectra were obtained from a metal halide
lamp (UVASUN 5000 Mutzhas, Munich, Germany) by using different
®lters: (i) a Schott WG335/3 mm thick ®lter (Clichy, France) and two
Schott UG5/3 mm thick ®lters that delivered a 320±400 nm radiation
spectrum (UVA), or (ii) a Schott WG360/2 mm thick and two Schott
UG5/3 mm thick ®lters delivering a 340±400 nm spectrum (UVA1).
The spectra are shown in Fig 1.
SSRÐStudy II The source used to compare two SPF 9 sunscreens (see
Results and Table II) was also the metal halide lamp (UVASUN 5000
Mutzhas, Munich, Germany) but equipped with ®lters to give a
spectrum between 290 and 390 nm: the ®lters were a Schott UG11/
3 mm thick ®lter (Clichy, France), and a Mutzhas custom made short
cut-off glass ®lter/8 mm thick (Munich, Germany).
Indoor dosimetry The spectral power distribution for the laboratory UV
radiation sources was measured with a calibrated spectroradiometer
Macam 3010 (Macam, Livingston, U.K.). The output was monitored
with a Centra OSRAM (Berlin, Germany) radiometer equipped with
UVB and UVA sensors.
Table I. The eight treatment groups used
Study no. Group no. No. of subjectsa Treatment Cumulative dose
I 1 8 F, 4 M No UV
2 6 F, 5 M 12 exposures
Full spectrum UVA
352 J per cm2
3 9 F, 2 M 12 exposures
UVA 1
352 J per cm2
II 4 10 F, 5 M 10 exposures
SSR
14.5 MED (SD = 2.3)
75 J per cm2 UVA (SD = 3.4)
5 12 F 10 exposures
SSR + sunscreen A
58 MED (SD = 4.5)
15 J per cm2 UVA (SD = 99.7)
6 6 F, 5 M 10 exposures
SSR + sunscreen B
58 MED (SD = 3.3)
315 J per cm2 UVA (SD = 63.6)
III 7 8 F, 8 M 6 d of exposure
Sunlight + sunscreen C
50.5 standardized MED
340 J per cm2 UVA
8 8 F, 8 M 6 d of exposure
Sunlight + sunscreen D
50.5 standardized MED
340 J per cm2 UVA
aF, female; M, male.
Figure 1. Emission spectra of the Uvasun5000 metal halide lamp.
The UVA 1 (340±400 nm) spectrum (± ± ±) was obtained with one
Schott WG 360/2 mm thick and two Schott UG5/3 mm thick ®lters.
The full UVA (320±400 nm) spectrum (sÐs) was obtained with one
Schott WG 335/3 mm thick and two Schott UG5/3 mm thick ®lters.
The SSR (290±390 nm) spectrum (Ð) was obtained with a short cut-off
glass ®lter/8 mm thick and a Schott UG11/3 mm thick ®lter.
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Natural sunlight Two sunscreens SPF25 were compared in a study
performed in outdoor under actual sun in Turkey (latitude 38°N) during
June 1999. The solar UV exposure of volunteers was monitored with an
2-channel PMA self-recording radiometer (Solar-Light Co, Philadelphia,
PA), equipped with a UV erythemal (280±380 nm) sensitive cell (UVe)
and a UVA (320±400 nm) sensitive cell. During exposure, the UVe
irradiance was recorded every 10 min on a horizontal plane and
expressed as erythemal effective (ee) intensity in terms of standard
minimal erythemal dose (MED) per hour (standard MED = 21 mJ per
cm2) (Solar-Light Inc., 1993). At the same time, UVA irradiance was
recorded as mW per cm2. The cumulative UV doses received by all
volunteers were calculated as standard MED (UVe) and J per cm2
(UVA).
Sunscreens For the indoor study II, two prototype sunscreen
preparations (A and B) were formulated in the same oil-in-water vehicle.
The products were designed to have the same SPF but different UVA-
PF. Their characteristics are shown in Table II.
SPF was determined according to the European Cosmetic Toiletry
and Perfumery Association (COLIPA) recommendations (1994) using the
metal halide lamp (290±390 nm), which was used for the immuno-
protection study (study I). UVA-PF was determined on 10 subjects using
an in vivo method based on persistent pigment darkening dose (Moyal
et al, 2000), a method adopted by the Japanese Cosmetic Industry
Association (JCIA) in, 1996. For the immunoprotection study, products
A and B were applied at 2 mg per cm2 15 min prior to each exposure
on both exposed body sites (see section on UV exposures).
For the outdoor study III, two commercially available sunscreen
products (C and D) were selected. Their characteristics are shown in
Table II. Products C and D had the same SPF 25 and their UVA-PF
were determined using the persistent pigment darkening method as
described above. Volunteers were exposed to sunlight after sunscreen was
applied over the whole body except on the areas covered by swim wear
and the opaque armband (see section on UV exposures), before each
exposure period. The amount of applied product was weighted and
calculations based on body surface indicated that it averaged out at
approximately 0.8 mg per cm2 per application.
The UV radiation transmission spectra (T) of the products were
obtained using a modi®ed Diffey and Robson (1989) method. In this
method, the UV radiation transmitted through a roughened quartz plate,
with and without sunscreen applied, was measured spectroradiometrically.
The monochromatic protection factors (mPF) were calculated (mPF = 1/
T) and represented as a function of wavelengths (Figs 2 and 3).
UV exposures Under laboratory conditions two exposure areas
(30 cm 3 20 cm) were delineated, one on the back and the other one
on the abdomen in order to expose a large part of the body and feasible
with the surface of the solar simulator beam. Both sites were exposed to
the same UV regimen.
UVA study I In group 2 (full-spectrum UVA) and group 3 (UVA1) 12
daily exposures were performed (Monday to Friday in the ®rst 2 wk and
Monday and Tuesday in the third week) on both delineated areas. In
both groups, to avoid erythema the UVA exposure dose was
progressively increased from 20 J per cm2 to 48 J per cm2 (increment of
10% every 2 d for 6 d followed by an increase of 12% each day for the
last 6 d). The cumulative UVA dose received was 352 J per cm2. The
daily UVA doses administered were realistic, considering that 20 J per
cm2 of UVA is equivalent to about 1 h sunlight on the French Riviera
Figure 2. Monochromatic protection factors of sunscreens A and
B. The mPF spectra of products A (Ð) and B (± ± ±) were generated by
spectroradiometric measurements between 290 and 400 nm according to
a modi®ed Diffey method. These spectra clearly show that protective
ef®cacy in the UVA range for product A is much higher than for
product B.
Figure 3. Monochromatic protection factors of sunscreens C and
D. The mPF spectra of products C (Ð) and D (± ± ±) were generated
by spectroradiometric measurements between 290 and 400 nm according
to a modi®ed Diffey method. Two broad-spectrum sunscreens having
similar SPF can differ signi®cantly in UVA absorption potency as shown
on these spectra.
Table II. UV ®lters in sunscreen products A, B, C, D and protection factors determined in humans
Study no. Products UV ®lters combination SPF UVA-PF
II A 9% OC + 2% PBSA + 0.7%
TDSA + 2% BMDM
9 (1.3) 9 (1.3)
B 9% OC + 1% PBSA 9.3 (1.6) 2.1 (1.3)
III C 10% OC + 0.5% TDSA + 2.5%
BMDM + 1.5% DT + 4%TiO2
25a 13.7 (2.8)
D 4-MBC + OT + BMDM + TiO2 25
a 5.9 (1.4)
aSPF labeled on the packaging. Mean (SD). Number of volunteers =10±12; OC, Octocrylene or Uvinulâ N539; PBSA: phenylbenzimidazole sulfonic acid or Eusolex
R232; TDSA, terephthalylidene dicamphor sulfonic acid or Mexoryl â SX; BMDM, butyl methoxydibenzoylmethane or Parsolâ 1789; DT, drometrizole trisiloxane or
Mexorylâ XL; 4-MBC, 4-methyl benzylidene camphor or Eusolex R6300; OT, octyl triazone or Uvinul RT150; TiO2: titanium dioxide.
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at noon in summer. The initial 20 J per cm2 are lower than an average
UVA MED, which is approximately 30 J per cm2 for Fitzpatrick skin
type II or III (Fitzpatrick, 1988).
Laboratory sunscreen study II Using the SSR source, the MED was
determined for each volunteer in groups 4, 5, and 6 on the upper part of
the back the day before the ®rst exposure.
In group 4 (SSR irradiated control), 10 daily exposures over 2 wk
were carried out on both delineated areas. The SSR dose was progres-
sively increased by 10% from 0.8 individual MED to 2 individual MED.
The cumulative SSR dose was on average 14.5 MED (SD = 2.3). The
UVA dose included was on average 75 J per cm2 (SD = 13.4). This
progressive approach was chosen to minimize erythema. If a perceptible
redness was observed 24 h after exposure, the dose was not increased.
In groups 5 (SSR + product A) and 6 (SSR + product B) SSR doses
on both delineated areas were increased at the same rate as in group 4,
but the doses were multiplied by half the SPF of sunscreens (Table II).
We chose to expose the skin to SSR doses that did not exceed the
protective ef®cacy of the sunscreens against erythema. So if 24 h after an
exposure a perceptible redness was observed, the dose was not increased
for the next exposure. The cumulative SSR dose delivered was on
average 58 individual MED (SD = 4.5 for group 5 and SD = 3.3 for
group 6) with an average UVA component of 315 J per cm2 (SD = 99.7
for group 5 and SD = 63.6 for group 6).
Outdoor sunscreen study III Groups 7 and 8 were each exposed to the
same daily solar UV radiation dose for 6 d, including an exposure both
each morning and each afternoon.
The duration of daily exposure ranged from 3 h (1st day) to 5 h (6th
day), thus the UV radiation dose was progressively increased from 6 to
10 standardized erythemal doses (MED = 21 mJ per cm2) per day (Solar-
Light Inc., 1993). All volunteers received the same cumulative dose of
50.5 standardized MED with a UVA component of 340 J per cm2. The
entire body was exposed except areas covered by the standardized swim
wear (bikini for females, slip for male) and one area (35 cm2) on one
arm, which was protected by an UV opaque armband. This area enabled
the distal effects of sun exposure to be assessed.
Immune response to recall antigens: elicitation of DTH
reaction The effects of UV radiation exposure on the elicitation of
DTH reaction were measured using Multitest Kits Pasteur/MeÂrieux
(Lyon, France). This Multitest kit includes seven antigens (tetanus
toxoid, diphtheria toxoid, Streptococcus, tuberculin, Candida albicans,
Trichophyton mentagrophytes, and Proteus mirabilis). As the negative control
substance, there was a 70% sterile glycerin solution, the antigen vehicle.
Measuring the immune response to recall antigens that most people
encounter during childhood immunizations, offers a unique advantage as
no active immunization of the test volunteer is required.
For the indoor studies, all Multitests were carried out on the back. An
initial test was done on the right or left side of the upper back the week
before UV exposure. Two subsequent tests were done 24 h after the last
UV radiation exposure: one on a nonexposed site for the evaluation of
distal immunosuppression (the opposite side of the ®rst Multitest) and
the other on the exposed site for the assessment of both local and distal
immunosuppression.
For the outdoor study, Multitests were carried out on the back
(exposed site) and on one arm (unexposed site) 1 wk before the ®rst
exposure and 72 h after the last sun exposure All DTH test responses
were measured 48 h after applying the Multitest.
The diameter (mm) of each positive reaction, identi®ed as erythema
accompanied by local induration, was measured in two directions and
averaged. The mean diameters of each positive reaction for each subject
were added to obtain the total score.
Statistical analysis Statistical comparisons were made by comparing
the DTH response after UV radiation exposure with DTH response
before UV radiation exposure in each subject via paired two-tailed
Student's t tests. Variance analysis between groups was performed to
compare results on the difference of the total scores (pre-UV±post-UV).
Results were considered signi®cant if p < 0.05 (software SPSS).
RESULTS
SPF and UVA-PF determinations The results are shown in
Table II. It can be seen that the SPF of the products were both 9
for indoor SSR study II but that product A had a much higher
UVA-PF (UVA-PF = 9) than product B (UVA-PF = 2.1). SPF
testing was not done for the sunscreens used in outdoor study III
but each had a labeled SPF of 25. Product C, however was shown
to have a much higher UVA-PF (UVA-PF = 13.7) than product D
(UVA-PF = 5.9).
Elicitation of local DTH response was decreased by repeated
UVA and SSR exposures
Study I and study II group 4 No signi®cant variation between the
response to the three Multitests was observed in control group 1,
which was not exposed to UV (Table III). In group 2 (full
spectrum UVA) and group 3 (UVA 1) a signi®cant (p < 0.05) and
equivalent decrease in the DTH responses was observed either on
the exposed or nonexposed sites when compared with the test done
before UVA exposure. Percent immune suppression ranged
between 57% and 67% (Table III). Under full spectrum UVA
exposure conditions we observed a slight erythema on the
volunteers from the fourth exposure up to the last exposure.
Under UVA 1 exposure conditions, we did not observe any
erythema, only a moderate tan was noticed.
In group 4, exposed to repeated low erythemal SSR doses
without sunscreen protection, there was a signi®cant decrease
(approximately 60%) (p < 0.05) in the response to antigens after
exposure as compared with the initial response. This decrease was
not signi®cantly different on exposed (71%) and nonexposed (59%)
skin sites (Table IV). The immunosuppressive effects were
equivalent to the one observed after repeated UVA or UVA 1
exposures (57±67%).
A moderate erythema developed in three volunteers after the
third exposure and in ®ve volunteers after the sixth exposure when
the daily SSR dose was 1.6 MED. The erythema was observed for
3 d before the onset of tan. The other volunteers only developed a
just perceptible erythema.
When the initial Multitests (before exposure) were compared
with unirradiated controls after UV radiation exposure, the
intensity of DTH response at unirradiated sites was signi®cantly
(p < 0.05) reduced by exposure of adjacent skin to the two UVA
protocols and SSR (Tables III and IV). Thus, all UV protocols
caused distal as well as local immunosuppression.
Indoor sunscreen study II A signi®cant decrease (p < 0.05) in the
response was observed in group 6 (SSR + sunscreen SPF 9 UVA-
PF 2) on both exposed (65%) and nonexposed (52%) skin sites.
There was no signi®cant difference (p > 0.05) in the immuno-
suppression rate measured between groups 4 (exposed unprotected)


















Pre-UV 10.8 6 2.9 8.1 6 2.1 17.3 6 2.4
Post-UV non-exposed site 12 6 3.4 + 11% 3.1 6 1.7a ± 61.7% 6.5 6 0.9a ± 62.4%
Post-UV exposed site 9.8 6 3.3 ± 9.3% 2.7 6 1.3a ± 66.7% 7.3 6 1.0a ± 57.8%
aSigni®cantly different from pre-UV (p < 0.05).
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and 6 (exposed protected with SPF 9 UVA-PF 2) on exposed and
nonexposed skin sites (Table IV).
In group 5 (SSR + broad-spectrum sunscreen SPF 9 UVA-PF 9)
the DTH response was slightly decreased (± 29.8%, p < 0.05) on
exposed sites and unchanged on nonexposed sites.
As the initial responses to Multitest were not different between
groups (p > 0.1) we compared the three groups and showed that
the difference in ef®cacy between the broad-spectrum product and
the nonbroad-spectrum product was highly signi®cant (p < 0.01)
for both local and distal immune suppression (Table IV). We did
not observe any sunburn in the study groups.
Outdoor sunscreen study III Both products were protective against
erythema, but the tan developed was signi®cantly higher on group
8 (protected by the SPF 25 UVA-PF 6 sunscreen) than on group 7
(protected by sunscreen SPF 25 UVA-PF 14).
The outdoor study demonstrated that, in comparison with DTH
responses before solar exposure, no alteration of local and distal
immune response was detected when the skin was protected by
sunscreen SPF 25 UVA-PF 14 (group 7). Conversely, in Group 8
on which sunscreen SPF 25 UVA-PF 6 was applied, a moderate
decrease (p < 0.1) in the immune response was observed on the
irradiated skin of the back (± 19.2%) (local effect) and a signi®cant
decrease (p < 0.05) was measured on the nonirradiated skin of the
arm (± 33%) (distal effect) (Table V).
DISCUSSION
Whereas it is generally agreed that UVB and SSR are immuno-
suppressive (Cooper et al, 1985; van Praag et al, 1991; Wolf et al,
1993), few data have been reported on the effects of UVA.
We have investigated the effects of UVA on the elicitation phase
of the DTH response. It was important to know if UVA could
affect this response and thereby possibly compromise the ability of
vaccination to trigger a response after contact with the relevant
antigen (Jeevan and Kripke, 1990). Needs for research on this issue
have recently been listed in Selgrade et al (1997). By measuring the
effects of different parts of the UV spectrum and the protection
afforded by sunscreens on immune DTH response to recall
antigens, we generated data relevant to the issue. In our studies
volunteers were exposed to repeated, realistic UVA doses.
Furthermore, we compared the effects of full spectrum UVA
(UVA) v long-wave UVA (UVA 1) and SSR. We also studied the
effects of UVA indirectly by comparing sunscreens having the same
SPF but with a different UVA-PF.
We have shown that the elicitation of DTH response was
signi®cantly reduced, both locally and at a distance, by all UV
radiation sources used. Furthermore, the exposure protocols we
applied resulted in a similar degree of immune suppression
irrespective of the source. Of course, the UV dose ranges tested
are limited but preliminary experiments from our group (data not
shown), with lower repeated doses of SSR (a total of 5 MED over
5 d) or with real sun exposure (1 MED per day for 12 d) resulted
also in a decrease of DTH reaction (decrease of 20% and 34%,
respectively). We never observed whatever the wavebands, the
exposure regimen or the UV dose, an enhancement of the
elicitation response to recall antigens. Sunscreen studies indirectly
con®rmed the suppressive effects of UVA by showing that products
having a similar SPF with higher UVA protection provided
signi®cantly better prevention that those with a low UVA
protection. It was evidenced both with SSR and natural sunlight.
These ®ndings con®rm those of Damian et al (1997) in humans
whereas our results without sunscreens con®rm those of Ullrich
(1999) who found that acute low SSR doses and full spectrum
UVA suppressed the DTH elicitation response to Candida albicans
in the mouse.
Few other investigators have studied the effects of UVA on the
elicitation phase of CHS or DTH responses. Damian et al (1999)
reported the effects of full spectrum UVA (320±400 nm) on the
elicitation of CHS response to nickel in humans. In this study, a
single low dose (4 J per cm2), was suppressive as were low-dose
exposures (1.9 J per cm2 per exposure) over 1±3 d. In contrast,
there were no suppressive effects when a low-dose cumulative
UVA exposure was applied over a longer period (4 d±4 wk). The
authors proposed the development of an adaptive response with
longer exposure periods.
Others (Hersey et al, 1983; LeVee et al, 1997; Skov et al, 1997)
have investigated the effects of UVA on the suppression of
induction phase of CHS response to chemical haptens. These
studies assessed the effects of UV radiation on cutaneous immune
Table V. Immunoprotection afforded by sunscreens (outdoor study III). Total score expressed in mm (mean 6 SEM) and










Pre-UV back site 20.8 6 2.3 21.2 6 2.4
Post-UV exposed back site 19 6 2.2 ± 8.6% 17.1 6 1.8a ± 19.3%
Pre-UV arm site 14.7 6 2.1 18.2 6 2.8
Post-UV non-exposed arm site 14 6 1.5 ± 4.8% 12.1 6 1.8b ± 33.5%
aDifferent from pre-UV (p < 0.1).
bSigni®cantly different from pre-UV (p < 0.05).
Table IV. Immunoprotection afforded by sunscreens (indoor study II). Total scores expressed in mm (mean 6 SEM) and















Pre-UV 10.7 6 1.5 13.1 6 2.9 13.3 6 3.3
Post-UV non-exposed site 4.4 6 0.9a ± 58.9% 11.5 6 2.4b ± 12.2% 6.3 6 1.9a ± 52.6%
Post-UV exposed site 3.1 6 0.6a ± 71% 9.2 6 1.9ab ± 29.8% 4.6 6 2.2a ± 65.4%
aSigni®cantly different from pre-UV (p < 0.05).
bSigni®cantly different from group 4 and group 6 for the same site (p < 0.01).
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function before sensitization, whereas studies on the elicitation
phase assessed the effects after sensitization. It should be stated,
however, that the immunologic and photobiologic relationships
between these two phases are unknown as well as their respective
role in tumor development.
LeVee et al (1997) reported that a single exposure to 4 MED
UVA 2 (centered at 335 nm) was highly effective to suppress CHS
induction by dinitrochlorobenzene; however, in another experi-
ment, 3 MED UVA 1 had no effect (Skov et al, 1997). In both
studies, there was no evidence of systemic suppression when
diphenylcyclopropenone was applied to a site distant from that
exposed to UVA, although LeVee et al (1997) showed that 4 MED
of UVA 2 had toleragenic effects. Hersey et al (1983) found that 12
cumulative exposures to UVA from a solarium delivering some
UVB (0.9±1.4% of total UV) suppressed the induction phase of
CHS response to dinitrochlorobenzene.
A recent study on the induction phase of CHS response to
dinitro¯uorobenzene in hairless mouse by Reeve et al (1998)
showed that a single UVA exposure, immediately after or before an
acute dose of 3 MED of UVB or SSR, abrogated the immuno-
suppressive effects. The effects of pure UVA applied before or after
UVB or SSR exposure, however, may not be relevant to real-life
conditions except perhaps for people using a sun parlor just before
solar exposure.
Donawho et al (1996) questioned whether UVB irradiation of
C3H mice could inhibit the elicitation of DTH response as well as
the rejection of melanoma cells. They demonstrated that elicitation
of a DTH response to alloantigen was diminished in UV irradiated
ears and that tumor rejection was impaired in melanoma immune
mice challenged in a UV-irradiated site. Our results showing that
UVA and SSR exposures suppress the elicitation of DTH to recall
antigens in humans con®rm these ®ndings in animals and suggest
that sunlight induces suppression of the efferent arm of immune
reaction. The suppression of the efferent arm may promote the
outgrowth of skin cancer.
Many investigators have studied the protective effects of
sunscreens on UV radiation-induced suppression of CHS or
DTH reactions in mice (Bestak et al, 1995; Roberts and Beasley,
1995; Gueniche and Fourtanier, 1997; Fourtanier et al, 2000) and
some in humans (Damian et al, 1997; Serre et al, 1997). The degree
of immune protection reported varies greatly.
Our study in humans con®rms previous results (Fourtanier et al,
2000) in the hairless mouse model in which the level of
immunoprotection afforded by two broad-spectrum sunscreens
having the same SPF but with different UVA-PF was evaluated.
Both sunscreens showed a preventive effect on UV-induced
suppression of CHS to dinitro¯uorobenzene but the product
having the higher UVA-PF showed signi®cantly greater protection.
An important conclusion of our study is that the SPF, an
indicator of protection against sunburn, is not a proper indicator of
the level of protection against the suppression of the elicitation
phase of immune response induced by repeated UV exposures. It
also strongly suggests that sunscreens with improved UVA
protection have a higher immune protection factor (IPF). In the
future it may be important to specify an IPF for sunscreen or at least
to demonstrate that the IPF is not lower than the SPF; however,
this would require the development of standardized methods based
on the dose±response characteristics of immunosuppression in
humans. Kelly et al (2000) have determined SSR dose±response for
the suppression of the induction phase of CHS response in humans.
Recently they have also studied the effects of a UVB sunscreen in
this model and they concluded that the IPF of the sunscreen was
about 50% of its SPF. The authors also suggested that UVA was
important in immunosuppression (personal communication).
The induction phase of CHS response in humans cannot be used
for the routine assessment of IPF as it necessitates sensitization that
can only be induced once. This means that only one person per UV
radiation dose can be studied subsequently requiring a large number
of volunteers to be involved if UV radiation dose±response studies
are to be carried out; however routine studies could be done on the
elicitation phase and it may be useful to make comparative studies
on immunoprotection of these two phases in relation to the SPF.
Our outdoor study, in which the volunteers self-applied the
sunscreens con®rmed previous reports that sunscreen users apply
less than 2 mg per cm2 in practice (Wulf et al, 1997; Azurdia et al,
1999). Overall, our calculations led to estimate an average applied
amount of 0.8 mg per cm2. Nevertheless the products performed
well, although it was observed a signi®cant difference in the
immunoprotection provided by the two products. These data
suggest to recommend applying a higher SPF than might be
actually needed in order to ensure that most adequate protection is
provided both against sunburn and the alteration of immune
function.
In conclusion, the present studies provide direct and indirect
evidence that UVA has a suppressive effect on cutaneous immunity
when assessed by the elicitation phase of DTH response. This effect
occurs on irradiated sites and on distal sites suggesting a possible
systemic effect.
The authors would like to thank Dr Antony. R. Young for reviewing the manuscript
and providing constructive comments.
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